FOR IMMEDIATE RELEASE
October 13, 2015
Media Contacts
Wiley:
Dawn Peters (US) +1 781-388-8408
Tom Griffin (UK) +44 (0) 1865 476213
Email: sciencenewsroom@wiley.com
Follow Wiley on Twitter @WileyNews
AIChE:
Jeanette Krebs +1 717-214-2200
Email: krebs@thebravogroup.com
NEW OPEN ACCESS JOURNAL WILL ADVANCE ENGINEERING
AND OPPORTUNITIES IN TRANSLATIONAL MEDICINE
AIChE and Society for Biological Engineering join forces with Wiley to launch
Bioengineering & Translational Medicine, with
Samir Mitragotri of the University of California, Santa Barbara, as editor-in-chief.
NEW YORK CITY-The American Institute of Chemical Engineers (AIChE) and its Society for
Biological Engineering (SBE), in partnership with John Wiley and Sons, are launching a new
quarterly, peer-reviewed, online, open-access journal, Bioengineering & Translational Medicine,
in 2016. To be part of the Wiley Open Access portfolio and edited by Samir Mitragotri of the
University of California, Santa Barbara, the new journal will focus on ways chemical and
biological engineering are driving innovations and solutions that impact clinical practice and
commercial healthcare products. The journal will also highlight scientific and technical
breakthroughs currently in the process of clinical and commercial translation.
In announcing Bioengineering & Translational Medicine, AIChE Executive Director June
Wispelwey said that the new journal represents “one of the latest and most significant examples
of the strengths that chemical and biological engineers bring to the frontiers of inter-disciplinary
research and its application.” She added that she was excited that the journal attracted “such an
esteemed editor in Dr. Mitragotri, and a very, very distinguished editorial advisory board.”
In discussing his plans for the journal, Mitragotri said, “Converting engineering advances into
useful clinical products is a major challenge that requires attention to issues such as safety,
manufacturability, regulatory hurdles, cost, and patient acceptance, among others.” These issues,
he pointed out, are not typically considered in fundamental academic research. “Clinical
translation also often needs concurrent consideration of commercial translation, with the team and
the resources required for clinical translation often assembled during commercial translation,” he
explained. He added that this interplay presents its own set of challenges.
Bioengineering & Translational Medicine welcomes manuscripts that provide new insights into
translational hurdles, as well as examples of technologies that have demonstrated progress toward
clinical or commercial translation. It invites contributions on topics including, but not limited to,
drug delivery, drug discovery, tissue engineering, synthetic biology, gene therapy, computational
modeling and bioinformatics, among others. (A more comprehensive list of topics can be found in
1
the journal’s statement of scope.) The journal will include research reports, reviews, and rapid
communications. Fully open access Bioengineering & Translational Medicine will be published
under CC-BY license.
Mitragotri concluded: “To researchers who are active, or aspiring to be active, in clinical and
commercial translation of biological technologies, I say ‘this is your journal.’ With a stellar
advisory board behind us, we are poised for an exciting, quick, and successful launch. We
promise a rapid and fair review and fast publication. We also welcome your suggestions and
comments on ways we can make the journal better serve your needs.”
Readership will include chemical engineers; biological engineers, biomolecular engineers,
biomedical engineers and other engineers and scientists with interests in translational medicine,
biotechnology, and biochemical and biomolecular engineering; and physicians and other
healthcare researchers and professionals.
Additional information is available at: http://www.aiche.org/biotm or by email at
biotm@aiche.org.
###
EDITORIAL ADVISORY BOARD:

Kristi Anseth, University of Colorado Boulder

Mark Davis, California Institute of Technology

Michael Deem, Rice University

Francis J. Doyle III, Harvard University

George Georgiou, University of Texas, Austin

Linda Griffith, Massachusetts Institute of Technology

Paula Hammond, Massachusetts Institute of Technology

Justin Hanes, Johns Hopkins University

Ravi Kane, Georgia Institute of Technology

Ali Khademhosseini, Harvard University

Chaitan Khosla, Stanford University

Cato Laurencin, University of Connecticut

Antonios Mikos, Rice University

Nicholas Peppas, University of Texas, Austin

Mark Prausnitz, Georgia Institute of Technology

W. Mark Saltzman, Yale University

David Schaffer, University of California, Berkeley

Gregory Stephanopoulos, Massachusetts Institute of Technology

David Tirrell, California Institute of Technology

Matthew Tirrell, University of Chicago

Jackie Ying, A*-STAR, Institute of Bioengineering and Nanotechnology
About SAMIR MITRAGOTRI:
Samir Mitragotri is a professor of Chemical Engineering at the University of California, Santa
Barbara (UCSB). He also serves as the founding director of UCSB’s Center for Bioengineering.
He received his PhD from MIT in 1996 and a BS from Institute of Chemical Technology, Mumbai
in 1992. Mitragotri’s research interests are in the field of drug delivery and biomaterials. His
2
research has advanced fundamental understanding of biological systems and led to the
development of new materials and technologies for diagnosis and treatment of various ailments
including diabetes, cardiovascular diseases and infectious diseases. Mitragotri is a prolific
author, an inventor with more than 100 pending or issued patents, and is a highly-cited
researcher. He has co-founded several companies that are developing products in therapeutics
and diagnostics. Mitragotri was recently elected to the National Academy of Engineering and has
received numerous awards and honor, including the 2015 Andreas Acrivos Award for
Professional Progress from AIChE.
About SBE:
Established in 2004, the Society for Biological Engineering is a technological community for
engineers and applied scientists integrating biology with engineering. Members of SBE come
from a broad spectrum of industries and disciplines and share in SBE’s mission of realizing the
benefits of bioprocessing, biomedical and biomolecular applications. http://bio.aiche.org.
About AIChE:
Founded in 1908, AIChE is a professional society of more than 50,000 chemical engineers in 100
countries. Its members work in corporations, universities and government using their knowledge
of chemical processes to develop safe and useful products for the benefit of society. Through its
varied programs, AIChE continues to be a focal point for information exchange on the frontiers
of chemical engineering research in such areas as energy, sustainability, biological and
environmental engineering, nanotechnology and chemical plant safety and security. More
information about AIChE is available at www.aiche.org.
About WILEY:
Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes
in areas of research, professional practice and education. Through the Research segment, the
Company provides digital and print scientific, technical, medical, and scholarly journals,
reference works, books, database services, and advertising. The Professional Development
segment provides digital and print books, online assessment and training services, and test prep
and certification. In Education, Wiley provides education solutions including online program
management services for higher education institutions and course management tools for
instructors and students, as well as print and digital content. The Company’s website can be
accessed at www.wiley.com.
3